ArticleJournal of diabetes investigation2025
A nomogram incorporating clinical and laboratory indicators for predicting metabolic dysfunction-associated fatty liver disease in newly diagnosed type 2 diabetes patients.
Article in Journal of diabetes investigation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
aimsTo develop and validate a nomogram model based on clinical and laboratory parameters to predict the risk of metabolic dysfunction-associated fatty liver disease (MAFLD) in the early stage of type 2 diabetes. MATERIALS AND
methodsWe performed this study among 883 inpatients with new-onset type 2 diabetes, and the data were divided randomly into training and validation groups. The logistic regression method was used to identify the independent risk factors of MAFLD, and a nomogram was established according to the logistic regression analysis and these selected parameters. The discrimination, calibration, and clinical utility of the nomogram were measured by receiver operating characteristic curve analysis, calibration curves, and decision-curve analysis, respectively.
resultsEight variables were identified and included in the nomogram (body mass index, alanine aminotransferase, triglyceride, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, fasting plasma glucose, urea nitrogen and serum uric acid). The value of the area under the receiver operating characteristic (ROC) curve was 0.898 for the training group and 0.92 for the validation group. The calibration plots indicated that this model had good accuracy, and the decision-curve analysis revealed high-clinical practicability of the nomogram.
conclusionsThis study established a convenient and practical nomogram model, which can be used as an easy-to-use tool to evaluate the risk of MAFLD among patients with newly diagnosed T2DM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.